Compare Gilead Sciences, Inc. (GILD) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Gilead Sciences, Inc. trades at $135.56 (market cap $163.51B), while iShares 0 3 Month Treasury Bond ETF trades at $100.54. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while iShares 0 3 Month Treasury Bond ETF pays none. Which is the better fit depends on your goals.
| GILD | SGOV | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Fixed Income |
52-Week High | $155.80 | $100.74 |
52-Week Low | $108.22 | $100.28 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.545, up 0.02% over 24 hours, with technical indicators showing a bullish trend from moving averages but mixed signals from oscillators. The ETF offers a low-risk cash alternative with a yield around 3.5–3.65% and minimal expense ratio of 0.09%, attracting significant investor inflows amid rate uncertainty. Recent news highlights its role in diversification and income strategies for conservative portfolios.
Outlook remains positive for SGOV as a safe-haven asset, benefiting from Federal Reserve policy speculation and demand for short-term yield. Risks include interest rate volatility and competition from similar ETFs. Wall Street sentiment is favorable, with analysts endorsing its cost efficiency and liquidity for cash management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
